Nanjing Vazyme Biotech Co., Ltd. (688105.SS) SHH

Currency In CNY

AD

Valuation

Market Cap6.53B
Enterprise Value6.54B
P/E Ratio3,746,994.89T
PEG Ratio14,485.73T
Price/Sales Ratio6.85
Price/Book Ratio1.01
Enterprise/Revenue7.01
Enterprise/EBITDA261.88

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.01
Operating Margin-0.02
AD

Management Effectiveness

Return On Assets-0
Return On Equity-0

Income Statement

Revenue1.38B
Revenue/Share7.84
Gross Profit-40.48M
EBITDA56.88M
Net Income-16.97M
Diluted EPS-0.04

Balance Sheet

Total Cash2.51B
Total Cash/Share13.38
Total Debt671.57M
Total Debt/Equity0.19
Current Ratio3.99
Book Value Per Share19.19

Price History

52-Week Change10.73
52-Week High27.6
52-Week Low12.89
Moving Average 50 Days19.95
Moving Average 200 Days16.68

Statistics

Average Volume12.4M
Shares Outstanding516.99M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.5
Trailing Annual Dividend Yield2.56
Payout Ratio-23.05
Last Split Factor13:10
Last Split DateJune 03, 2026
AD